loading...
Antero Peak Group Portfolio Manager Chris Smith recently joined Agilent Technologies CFO Bob McMahon to discuss how increased investment in research and development is advancing bleeding edge life science tools and technologies.

This Peak Insights replay represents the views and opinions of Chris Smith and Bob McMahon as of 15 Jun 2021, which are based on current market conditions, will fluctuate, and are subject to change without notice. While the information contained herein is believed to be reliable, there no guarantee to the accuracy or completeness of any statement in the discussion. This material is for informational purposes only and should not be considered as investment advice or a recommendation of any investment service, product or individual security. Any forecasts contained herein are for illustrative purposes only and are not to be relied upon as advice or interpreted as a recommendation.

Investments will rise and fall with market fluctuations and investor capital is at risk. Past performance does not guarantee future results.

For the purpose of determining the portfolio’s holdings, exposures are delta-adjusted at the issuer level and may include multiple securities of the same issuer. The holdings mentioned above comprised the following percentages of a representative account within the Antero Peak Strategy Composite’s total net assets as of 15 Jun 2021: Agilent Technologies Inc. 0.5%. Securities named in the video, but not listed here are not held in the portfolio as of 15 Jun 2021. Portfolio holdings are subject to change without notice. The discussion of portfolio holdings does not constitute a recommendation of any individual security.